Heart repair with stem cells: a new hope for chronic heart failure?

NCT ID NCT06340048

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether injecting lab-grown heart muscle cells (HiCM-188) into the heart during bypass surgery can safely help people with severe chronic heart failure. About 36 adults with damaged heart tissue and reduced pumping function will receive the cell injection. The main goal is to check for serious side effects within the first month, while also looking at heart function and tumor risk over a year.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Allogeneic human pluripotent stem cell-derived cardiomyocytes (HiCM-188)
What this could lead to
If successful, this could lead to a new way to repair damaged heart muscle in people with severe heart failure, potentially improving heart function and quality of life.
What could go wrong
This is an early-phase trial with only 36 participants, so results may not apply to everyone. Risks include serious side effects like arrhythmias, heart attack, or stroke, and it is unknown if the cells will work long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • TEDA International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, 300457, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.